Showing 1,121 - 1,140 results of 1,242 for search 'first baseman~', query time: 3.09s Refine Results
  1. 1121

    DepRescribing inapprOpriate Proton Pump InhibiTors (DROPIT): study protocol of a cluster-randomised controlled trial in Swiss primary care by Stefan Neuner-Jehle, Katharina Tabea Jungo, Sven Streit, Sven Trelle, Nicolas Rodondi, Carole Elodie Aubert, Kristie Rebecca Weir, Enriqueta Vallejo-Yagüe, Samantha Chan, Marie Roumet, Pascal Juillerat, Sofia Carolina Zambrano Ramos, Jennifer Inauen, Angela Edith Schulthess-Lisibach, Renata Vidonscky Lüthold, Clémentine Tombez, Martina Zangger, Flurina Jenal, Yvonne Mattmann, Christof Bieri, Michaela Barbier

    Published 2025-01-01
    “…Data will be collected at baseline, 3-, 6-, 9- and 12-month follow-up time through online surveys or a phone call for both GPs and participants.Primary and secondary outcome measures The first co-primary endpoint is the effectiveness of the deprescribing intervention measured by the change of prescribed PPI dose. …”
    Get full text
    Article
  2. 1122
  3. 1123
  4. 1124
  5. 1125
  6. 1126

    Artificial intelligence-assisted clinical decision support for childhood asthma management: A randomized clinical trial. by Hee Yun Seol, Pragya Shrestha, Joy Fladager Muth, Chung-Il Wi, Sunghwan Sohn, Euijung Ryu, Miguel Park, Kathy Ihrke, Sungrim Moon, Katherine King, Philip Wheeler, Bijan Borah, James Moriarty, Jordan Rosedahl, Hongfang Liu, Deborah B McWilliams, Young J Juhn

    Published 2021-01-01
    “…While the proportion of children with AE in both groups decreased from the baseline (P = 0.042), there was no difference in AE frequency between the two groups (12% for the intervention group vs. 15% for the control group, Odds Ratio: 0.82; 95%CI 0.374-1.96; P = 0.626) during the study period. …”
    Get full text
    Article
  7. 1127

    Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms by Esther Natalie Oliva, Shien Guo, Jennifer Lord-Bessen, Aylin Yucel, Roberto Latagliata, Massimo Breccia, Giuseppe A. Palumbo, Grazia Sanpaolo, Marta Riva, Valeria Santini, Uwe Platzbecker, Guillermo Garcia-Manero, Pierre Fenaux, Christopher G. Pelligra

    Published 2025-02-01
    “…It contains 29 items with the first two items assessing the patient’s general well-being and the 27 remaining items grouped into six domain scores: physical well-being (QOL-FIS), functional well-being (QOL-FUN), social/family well-being (QOL-SOC), sexual well-being (QOL-SEX), fatigue (QOL-FAT), and MDS-specific disturbances (QOL-MDSS). …”
    Get full text
    Article
  8. 1128

    Clinical risk score to predict in-hospital mortality in COVID-19 patients: a retrospective cohort study by Adriano Peris, Andrea Ungar, Niccolò Marchionni, Federico Lavorini, Alessandro Bartoloni, Stefano Fumagalli, Rossella Marcucci, Giulia Cesaroni, Riccardo Pini, Carlo Nozzoli, Carlo Fumagalli, Renzo Rozzini, Matteo Vannini, Flaminia Coccia, Francesca Mazzeo, Maria Cola, Paolo Fontanari, Alessandro Morettini, Filippo Pieralli, Loredana Poggesi

    Published 2020-09-01
    “…In the present study, we aimed to develop a clinical risk score to predict the in-hospital mortality in COVID-19 patients, based on a set of variables available soon after the hospitalisation triage.Setting Retrospective cohort study of 516 patients consecutively admitted for COVID-19 to two Italian tertiary hospitals located in Northern and Central Italy were collected from 22 February 2020 (date of first admission) to 10 April 2020.Participants Consecutive patients≥18 years admitted for COVID-19.Main outcome measures Simple clinical and laboratory findings readily available after triage were compared by patients’ survival status (‘dead’ vs ‘alive’), with the objective of identifying baseline variables associated with mortality. …”
    Get full text
    Article
  9. 1129

    SHoes for Adolescent PatEllofemoral pain: study protocol for the SHAPE Australian community-based, randomised clinical trial by Kim L Bennell, Kade L Paterson, Rana S Hinman, Jo-Anne Manski-Nankervis, Adam Bryant, Karen Elaine Lamb, Peixuan Li, Sam Shearer, Anurika P De Silva

    Published 2025-02-01
    “…The SHoes for Adolescent PatEllofemoral pain trial will provide the first RCT evidence on the efficacy of minimalist shoes compared with motion control shoes in adolescents with patellofemoral pain. …”
    Get full text
    Article
  10. 1130

    Effects of nurse-home visiting on intimate partner violence and maternal income, mental health and self-efficacy by 24 months postpartum: a randomised controlled trial (British Col... by Susan Jack, Charlotte Waddell, Michael Boyle, Harriet MacMillan, Yufei Zheng, Hui Xie, Colleen Varcoe, Amiram Gafni, Andrea Gonzalez, Debbie Sheehan, Lil Tonmyr, Ronald Barr, Lenora Marcellus, Nicole L A Catherine

    Published 2025-01-01
    “…At 24 months postpartum, for participants receiving NFP, a lower percentage reported IPV (group difference −7.14; 95% CI: –14.17, –0.10); incomes were larger ($1629.74, 95% CI: $5.20, $3254.28) after adjusting for baseline differences and no difference in percentage of NEET (−2.41, 95% CI: −10.11, 5.30). …”
    Get full text
    Article
  11. 1131
  12. 1132

    Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE‐4.5 study by Susanne Klein‐Scory, Alexander Baraniskin, Wolff Schmiegel, Thomas Mika, Roland Schroers, Swantje Held, Kathrin Heinrich, David Tougeron, Dominik P. Modest, Ingo Schwaner, Jan Eucker, Rudolf Pihusch, Martina Stauch, Florian Kaiser, Christoph Kahl, Meinolf Karthaus, Christian Müller, Christof Burkart, Sebastian Stintzing, Volker Heinemann

    Published 2025-02-01
    “…The randomized FIRE‐4.5 (AIO KRK0116) trial compared first‐line therapy with FOLFOXIRI (folinic acid, fluorouracil, oxaliplatin, and irinotecan) plus either cetuximab or bevacizumab in B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) V600E‐mutant metastatic colorectal cancer (mCRC) patients. …”
    Get full text
    Article
  13. 1133

    Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial by Norberto Chavez-Tapia, Muneeba Ahsan Sayeed, Shobha Luxmi, Douglas J. Kasper, Fenchao Xue, Yang Shen, Weiliang Fan, Wei Yuan, Bin Du

    Published 2025-01-01
    “…Fewer SIR1-365-treated vs. placebo-treated patients experienced TEAEs (30.4% vs. 57.9%) and serious TEAEs (13.0% vs. 26.3%) within 28 days of the first dose. There were no serious treatment-related TEAEs or deaths. …”
    Get full text
    Article
  14. 1134

    Cardiovascular risk associated with glucagon-like peptide-1 receptor agonists versus other conventional glucose-lowering drugs in patients with type-2 diabetes: protocol for a nati... by François Schiele, Mikael Mazighi, Nicolas Danchin, Igor Sibon, Gilles Lemesle, Kamel Mohammedi, Laurent Fauchier, Bruno Detournay, Alexandre Caron, Corinne Emery, Camille Nevoret, Lucile Vigié, Christine Massien

    Published 2025-01-01
    “…These cohorts will be defined by the combination of glucose-lowering drugs prescribed simultaneously with GLP1-RA and diabetes treatment received over a 6-month period before GLP1-RA initiation. They will be first matched with T2D controls (1:3 ratio) based on the year of drug initiation and treatment regimens before and simultaneously with GLP1-RA in the different selected cohorts. …”
    Get full text
    Article
  15. 1135
  16. 1136
  17. 1137
  18. 1138

    Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the... by Bruno Fautrel, Yoram Bouhnik, Carine Salliot, Franck Carbonnel, Mathurin Fumery, Christophe Bernardeau, Yves Maugars, Mathurin Flamant, Fabienne Coury, Ben Braithwaite, Salima Hateb, Janet Addison, the PERFUSE investigators

    Published 2024-10-01
    “…Among naïve patients, 12-month remission/low activity rates were 58% for RA, 66% for PsA, 59% for AS, 94% for CD, and 85% for UC, increasing significantly from baseline for all indications (p < 0.05). Switched patients’ remission rates remained stable between baseline and month 12 (M12) for all indications (p > 0.05). …”
    Get full text
    Article
  19. 1139

    Association of Estimated Glomerular Filtration Rate (eGFR) and High-Sensitivity C-Reactive Protein (Hs-CRP) with the Risk of New-Onset Atrial Fibrillation in Patients with Diabetes by Liu Y, Liu H, Sun D, Zheng Y, Tse G, Chen K, Qiu J, Wu S, Liu T

    Published 2025-01-01
    “…These findings remained consistent after excluding AF cases within the first 2-year. No significant interaction between eGFR and hs-CRP was observed (P=0.227). …”
    Get full text
    Article
  20. 1140

    The measurement of microplastics in surface water and their impact on histopathological structures in wading birds of district Lahore by Shaza Mehboob, Khalid Mahmood Anjum, Hamda Azmat, Muhammad Imran

    Published 2025-01-01
    “…Plastics are globally considered a significant threat, particularly to metropolitan areas, due to the extensive use of plastic products. This research is the first of its kind to document microplastics contamination and its effects on Red wettled lapwing (Vanellus indicus). …”
    Get full text
    Article